In Biotech Sector, during Tuesday’s Trade:
- Anthera Pharmaceuticals Inc (NASDAQ:ANTH), is the top gainer of the healthcare sector for the current trading session, and added 25.00% to the share.
- Biocept Inc (NASDAQ:BIOC), is among the top loser of the sector, losing -32.04% from the share, and is now trading at $1.23.
- Pfizer Inc (NYSE:PFE), recently hits new 52-week high of $34.22, and is now trading at $34.15.
- Biocept Inc (NASDAQ:BIOC), recently hits new 52-week low of $1.09, and is now trading at $1.23.
- Anthera Pharmaceuticals Inc (NASDAQ:ANTH), is the most volatile stock in the meantime, and it remained 7.82% volatile for the week and 9.59% for the month.
- Pfizer Inc (NYSE:PFE), is the most active stock for the session, and is now gaining volume of 59.4M.
- Cablevision Systems Corporation (NYSE:CVC), will release their earning report, before the market close today.
Biocept, Inc. (NASDAQ:BIOC), traded in a 52-week range of $1.09 to $9.70, hitting new 52-week low of $1.09, with shares dropped -33.51% at $1.23 in its last trading session, as a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, recently declared the pricing of an underwritten public offering of 8,000,000 shares of its ordinary stock and warrants to purchase up to an aggregate of 8,000,000 shares of its ordinary stock at a combined offering price of $1.25. The warrants will have a per share exercise price of $1.56, are exercisable right away and will expire five years from the date of issuance. The gross proceeds to Biocept from this offering are predictable to be about $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Biocept has granted the underwriters a 45-day option to purchase up to an additional 1,200,000 shares of ordinary stock and/or 1,200,000 additional warrants to cover over-allotments, if any. The offering is predictable to close on February 13, 2015, subject to customary closing conditions.
Aegis Capital Corp. and Feltl and Company, Inc. are acting as joint book-running managers for the offering.
Biocept, Inc. (NASDAQ:BIOC), headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients’ tumors to physicians using its proprietary technology platform to assist improve individual patient treatment.
Acorda Therapeutics, Inc. (NASDAQ:ACOR), declined -9.65% and settled at $36.06, following the news that a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders, formerly declared that Michael Rogers, Chief Financial Officer, and Andrew Blight, Chief Scientific Officer, will present at the 2015 Leerink Global Healthcare Conference in New York on Thursday, February 12 at 1:50pm.
Acorda Therapeutics, Inc. (NASDAQ:ACOR), is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda markets three FDA-approved therapies, counting AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an raise in walking speed.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO), dipped nearly -3.16% to $7.66, hitting new 52-week low of $7.45, The stock volatility for the week is 4.76%, while for the month, it is 4.50%. With recent decline, the year-to-date (YTD) performance reflected a -16.56% decline above last year. During the past month the stock lost -19.28%, bringing three-month performance to -31.79% and six-month performance to -14.60%.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO), together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases.
XOMA Corporation, (NASDAQ:XOMA), showed a negative movement of -0.60% to end at $3.29, hitting new 52-week low of $3.22. The stock volatility for the week is 4.05%, while for the month, it is 6.03%. With recent decline, the year-to-date (YTD) performance reflected a -8.36% decline above last year. During the past month the stock lost -10.11%, bringing three-month performance to -13.65% and six-month performance to -22.04%.
XOMA Corporation, (NASDAQ:XOMA), discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis, Behçets uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, cardiovascular disease, Schnitzler syndrome, and other diseases, in addition to diseases under the neutrophilic dermatoses designation; and various proof-of-concept studies, counting polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
CymaBay Therapeutics, (NASDAQ:CBAY), traded in a 52-week range of $4.47 to $13.78, with shares dropped -2.34% at $11.70 in its last trade, as a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders, formerly on January 28, declared results from a preclinical study indicating the potential for MBX-8025 to decrease low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that, in previous clinical studies, has been shown to reduce LDL-C in patients with mixed dyslipidemia. CymaBay believes that MBX-8025 has the potential to markedly improve the lipid profile of patients with various forms of dyslipidemia, counting HoFH.
CymaBay Therapeutics, (NASDAQ:CBAY), is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, counting serious rare and orphan disorders. Arhalofenate, the company’s lead product candidate, has shown two therapeutic actions in a single drug in three preceding Phase 2 gout studies.
